FDA reschedules Breo advisory committee meeting

FDA's Pulmonary-Allergy Drugs Advisory Committee will now meet on April 17 to discuss an NDA from Theravance Inc. (NASDAQ:THRX) and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for Breo fluticasone furoate/vilanterol to treat chronic obstructive pulmonary disease (COPD). The committee was originally scheduled to meet on March 7 to discuss the NDA, but the meeting was postponed due to adverse weather. Theravance was off $0.02 to $23.60 on Wednesday (see BioCentury Extra, March 5). ...